sfa 13:0

SFA 13:0, also known as tridecanoic acid or tridecylic acid, is a saturated fatty acid with a 13‑carbon straight chain. As an odd‑chain saturated fatty acid (OCSFA), it differs from the more abundant even‑chain saturated fatty acids such as palmitic (C16) and stearic (C18) acids. Chemically designated C13:0 in lipid nomenclature, tridecanoic acid has the structural formula CH3(CH2)11COOH and occurs as a white crystalline solid. Its hydrophobic nature makes it practically insoluble in water but soluble in organic solvents, reflecting typical properties of long hydrocarbon chain fatty acids. Tridecanoic acid is present in trace amounts in human plasma and tissues, and its presence is primarily attributed to exogenous dietary sources and microbial metabolism rather than significant endogenous synthesis. The unique metabolic fate of odd‑chain fatty acids involves mitochondrial β‑oxidation that yields not only acetyl‑CoA but also propionyl‑CoA, which can be converted into succinyl‑CoA to replenish tricarboxylic acid (TCA) cycle intermediates, thereby supporting gluconeogenesis during fasting states. While odd‑chain saturated fatty acids such as pentadecanoic (C15:0) and heptadecanoic (C17:0) acids have been studied as potential biomarkers of dairy intake and metabolic health, tridecanoic acid specifically remains less characterized in the scientific literature due to its scarcity and low circulating concentrations. Emerging research from targeted lipidomics and analytical studies suggests that tridecanoic acid may serve as a sensitive indicator of diet and microbiome interactions, but its direct physiological roles and clinical significance are still under investigation. Importantly, unlike essential nutrients such as vitamins and minerals, there are no established dietary reference intakes (DRIs) or recommended daily allowances (RDAs) for tridecanoic acid, and no deficiency syndromes have been identified. Its contribution to total dietary saturated fat intake is considered alongside other saturated fatty acids when evaluating dietary patterns and health outcomes.

The biological functions of tridecanoic acid are tied to its metabolic processing rather than to essential nutrient roles. Upon ingestion, tridecanoic acid is activated to tridecanoyl‑CoA and undergoes sequential β‑oxidation within mitochondria, producing acetyl‑CoA and propionyl‑CoA. This latter product enters the methylmalonyl pathway and converts to succinyl‑CoA, feeding into the TCA cycle and providing anaplerotic support to energy metabolism, particularly during fasting or low carbohydrate states. This pathway distinguishes odd‑chain saturated fatty acids from even‑chain counterparts that yield only acetyl‑CoA. While direct human clinical trials specifically evaluating tridecanoic acid intake and health outcomes are sparse, studies on odd‑chain saturated fatty acids collectively have linked higher circulating levels of certain OCFAs (notably C15:0 and C17:0) with lower risk for type 2 diabetes and cardiometabolic diseases, suggesting that odd‑chain fats may reflect healthier dietary patterns or microbiome activity rather than being causative agents of benefit. Emerging analytical work proposes that tridecanoic acid may also influence inflammatory signaling and gene expression through propionyl‑CoA derived metabolites, though direct evidence is limited and primarily inferred from research on similar odd‑chain fatty acids. Because saturated fats overall increase LDL cholesterol levels, major dietary guidelines from the World Health Organization and other authoritative bodies recommend limiting total saturated fat intake to reduce cardiovascular disease risk; however, these recommendations do not distinguish among individual saturated fatty acids by chain length. As such, while tridecanoic acid participates in energy metabolism, no specific health benefits have been conclusively established, and its effects are typically considered within the broader context of saturated fat intake and dietary quality.

Unlike essential micronutrients, there are no established RDAs, Adequate Intakes (AIs), or Reference Daily Intakes (RDIs) for tridecanoic acid because it is not considered an essential nutrient with a defined physiological requirement. The NIH Office of Dietary Supplements provides comprehensive DRI tables and Daily Values for nutrients that are essential for human health, but odd‑chain saturated fatty acids such as C13:0 are not included in these databases due to the lack of evidence indicating a requirement for health. Instead, dietary guidance for fatty acids focuses on total saturated fat intake rather than specific fatty acids. The Dietary Reference Intake framework and Daily Values developed for labeling consider total fat and fatty acid subclasses such as essential polyunsaturated fatty acids but do not provide specific targets for tridecanoic acid. For example, the NIH and public health agencies recommend keeping saturated fat intake below 10% of total daily calories to support cardiovascular health. Influencing factors such as age, sex, energy needs, metabolic health, and overall diet composition inform these recommendations rather than discrete needs for trace fatty acids. Furthermore, odd‑chain fatty acids are present in such small quantities in foods that targeting specific intake levels for C13:0 is not practical or recommended. Instead, clinicians and dietitians emphasize balanced dietary patterns that include a variety of fat sources, prioritizing unsaturated fats from plant oils, nuts, seeds, and fish while moderating foods high in saturated fats. Because tridecanoic acid occurs naturally in dairy fats and other foods, typical omnivorous diets will provide small, variable amounts without intentional supplementation or targeted intake levels.

Because tridecanoic acid is not considered essential, there are no defined deficiency symptoms associated with inadequate intake. No clinical deficiency syndrome has been reported for C13:0, and its concentrations in human plasma are typically low and influenced by diet and gut microbial metabolism rather than essential physiological needs. Unlike essential fatty acids such as linoleic acid or alpha‑linolenic acid, which are needed to maintain cell membrane integrity and produce eicosanoids, odd‑chain saturated fatty acids do not serve critical roles that, when absent, lead to overt pathology. Research into odd‑chain fatty acids has focused largely on their use as biomarkers of dietary intake, particularly from dairy and ruminant fats, and their associations with cardiometabolic risk factors. In the absence of acute deficiency symptoms, the scientific community has not identified specific clinical signs linked to low levels of tridecanoic acid. Laboratory measurements of odd‑chain fatty acids in blood or plasma are primarily used for research purposes rather than clinical diagnosis. At‑risk populations for low odd‑chain fatty acid exposure would include individuals who consume minimal ruminant fats or dairy products, but again, there is no evidence that low C13:0 per se causes health problems. Therefore, clinical evaluation focuses on overall dietary quality and established nutritional deficiencies rather than isolated C13:0 levels.

Tridecanoic acid occurs in trace amounts in a variety of foods, particularly those derived from ruminant animals and certain spices. According to nutrient ranking data, foods with measurable levels of C13:0 include dairy products such as reduced‑fat milk and American cheese, as well as spice powders like curry and chili powder that contain micro amounts of short‑chain and odd‑chain fatty acids. Trace quantities have also been reported in soups, baked goods, and some seafood such as ocean trout. Because tridecanoic acid comprises only a small fraction of total fat in foods, amounts per serving are low relative to other fatty acids. Nonetheless, including a variety of whole foods in the diet will provide these fatty acids incidentally. It is important to emphasize that total saturated fat content, not C13:0 specifically, drives dietary recommendations regarding saturated fats. Foods high in total saturated fats such as full‑fat dairy, fatty meats, and certain baked goods should be consumed in moderation in the context of overall dietary patterns that support cardiovascular health. In contrast, foods that supply beneficial unsaturated fats, fiber, and micronutrients are recommended. While C13:0 presence may serve as an analytical marker for dairy intake, nutrition guidance prioritizes overall dietary quality rather than targeting tridecanoic acid intake.

Like other dietary fatty acids, tridecanoic acid is incorporated into triglycerides and absorbed in the small intestine following digestion. Pancreatic lipases hydrolyze triglycerides to free fatty acids and monoglycerides, which are then incorporated into micelles and absorbed into enterocytes. Fatty acids including C13:0 enter the lymphatic system packaged in chylomicrons and are transported into systemic circulation. Once absorbed, odd‑chain fatty acids undergo β‑oxidation in mitochondria, yielding acetyl‑CoA and propionyl‑CoA. Because propionyl‑CoA can be metabolized to succinyl‑CoA, odd‑chain fatty acids can contribute to anaplerotic replenishment of the TCA cycle. Compared to long‑chain even saturates, odd‑chain fatty acids may have distinct metabolic fates, but specific absorption rates for C13:0 relative to other fatty acids are not well quantified due to their low dietary abundance. Factors that influence fat absorption generally, such as the presence of bile salts, dietary fiber, and overall fat content, will affect the bioavailability of tridecanoic acid similarly to other fatty acids.

There are no established supplements specifically containing tridecanoic acid for health purposes. Because C13:0 is present only in trace amounts in foods and has not been demonstrated to have essential nutrient functions, supplementation is not advised outside of research contexts. Dietary supplements targeting fatty acids typically focus on essential polyunsaturated fats such as omega‑3 EPA and DHA, which have well‑documented roles in cardiovascular and cognitive health. The NIH Office of Dietary Supplements provides fact sheets for nutrients with established health benefits and intake recommendations, but tridecanoic acid is not among them. As with other odd‑chain fatty acids, any potential health associations remain speculative and are primarily derived from observational research on related OCFAs like C15:0 and C17:0. Individuals interested in improving their fatty acid profile should focus on consuming a balanced diet rich in unsaturated fats and whole foods rather than seeking specific C13:0 supplements, and consult healthcare professionals when considering any supplement regimen.

No Tolerable Upper Intake Level (UL) has been established for tridecanoic acid. Because of its low abundance in foods and lack of clinical toxicity data in humans, there are no defined toxicity thresholds. Some animal data indicate that very high doses of tridecanoic acid can be toxic in laboratory settings, but these conditions are not relevant to typical dietary exposures. Dietary guidelines concerning saturated fats focus on overall intake rather than individual fatty acids; excessive consumption of saturated fats has been linked with increased LDL cholesterol and cardiovascular risk, and public health agencies recommend limiting total saturated fat intake to less than 10% of total calories to support heart health. Within this context, occasional ingestion of foods containing tridecanoic acid contributes only marginally to overall saturated fat intake.

There are no known drug interactions specific to tridecanoic acid due to its trace dietary presence and lack of use as a therapeutic agent. In general, dietary fats can influence the absorption of fat‑soluble medications and nutrients, but tridecanoic acid itself does not have documented interactions with medications. Clinicians should consider the effects of overall dietary fat intake on drug pharmacokinetics and patient health rather than focusing on individual fatty acids such as C13:0.